Compare BCBP & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCBP | NRXP |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.3M | 151.1M |
| IPO Year | 2005 | 2017 |
| Metric | BCBP | NRXP |
|---|---|---|
| Price | $8.63 | $2.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $8.95 | ★ $38.25 |
| AVG Volume (30 Days) | 368.6K | ★ 549.6K |
| Earning Date | 10-26-2026 | 11-16-2026 |
| Dividend Yield | ★ 3.73% | N/A |
| EPS Growth | N/A | ★ 69.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,225,000.00 |
| Revenue This Year | N/A | $363.65 |
| Revenue Next Year | N/A | $1,773.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.31 | $1.65 |
| 52 Week High | $11.71 | $5.06 |
| Indicator | BCBP | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 44.29 | 32.10 |
| Support Level | $8.50 | $2.81 |
| Resistance Level | $8.91 | $3.25 |
| Average True Range (ATR) | 0.23 | 0.15 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 58.22 | 8.16 |
BCB Bancorp Inc is a bank holding company. The company offers loans, including commercial and multi-family real estate loans, home equity loans, construction loans, consumer loans, and commercial business loans; FDIC-insured deposit products, such as savings and club accounts, interest and non-interest bearing demand accounts, money market accounts, certificates of deposit and individual retirement accounts, and retail and commercial banking services, including wire transfers, money orders, safe deposit boxes, a night depository, debit cards, online banking, gift cards, fraud detection and automated teller services.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.